The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedcentric Regulatory News (RCN)

Share Price Information for Redcentric (RCN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 142.00
Bid: 142.00
Ask: 144.00
Change: 0.75 (0.53%)
Spread: 2.00 (1.408%)
Open: 143.00
High: 143.00
Low: 142.00
Prev. Close: 142.25
RCN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on forensic review and remedial action plan

13 Dec 2016 15:07

RNS Number : 7479R
Redcentric PLC
13 December 2016
 

 

13 December 2016

Redcentric plc

("Redcentric" or the "Company")

 

Update on forensic review and remedial action plan

 

Redcentric (AIM:RCN) provides the following update on the progress made with its forensic review previously announced on 7 November 2016.

 

Initial findings from the forensic review 

 

As previously announced, following an internal review by the Company's audit committee in relation to the interim results for the six months ended 30 September 2016, misstated accounting balances in the Group's balance sheet were discovered. Redcentric promptly appointed Deloitte LLP ("Deloitte") and Nabarro LLP ("Nabarro") to carry out an independent forensic review.

 

The forensic review and management's initial findings are as follows.

 

• Net assets impairment: The cumulative overstatement of net assets and profits after tax up to 30 September 2016 is approximately £20.8 million. The current position is that approximately £5.9 million of this misstatement (£4.7 million at the EBITDA level) arose in the six months ended 30 September 2016 and will be reflected in the Company's interim results when they are published this month. The remaining £14.9 million misstatement relates to periods prior to and including the year ended 31 March 2016. To date there has been no evidence of theft and the misstatements are attributable to profit overstatement over a number of years with revenues being overstated and costs understated in broadly equal proportions.

 

• Net debt: As previously reported, the net debt position for both 31 March 2016 and 30 September 2016 is materially higher than originally reported. As at 31 March 2016, net debt was £37.8 million and as at 30 September 2016 net debt was £34.4 million.

 

However, the net debt position as at the period ends mentioned above are not representative because creditors had been significantly stretched at those dates. The average month end net debt position over the past eight months to 30 November 2016 was £42.0 million. This is expected to reduce as billing and debtor collection processes are improved.

 

Banking covenants

  

As noted in the announcement on 7 November 2016, the Company has recalculated its historic banking covenants due to the impact of various accounting adjustments. The Company is pleased to report that it has secured waivers from its Banks in relation to historic covenants such that it is fully compliant with its facilities. The Banks remain supportive of Redcentric and constructive discussions are ongoing in relation to the agreement of future covenant levels which reflect management's business plan.

 

Remedial action plan

 

As well as promptly appointing Deloitte and Nabarro to carry out the independent forensic review, management have also prepared and are executing a remedial plan of action.

 

Some important first steps have been made. These include the appointment of Peter Brotherton as Chief Financial Officer and Julian Llewellyn as Interim CFO. Both are based at Redcentric's headquarters in Harrogate. A full review of the entire finance function is underway, being directly led by Peter Brotherton.

 

A number of initial improvements have already been made including changes to billing and credit control management systems and processes. The restructuring of the finance function will continue as necessary.

 

Interim results announcement and outlook

 

The Company will report its interim results before 31 December 2016.

 

The Company currently expects to report for the six months ended 30 September 2016 revenue of approximately £53.0 million and EBITDA* of approximately £9.1 million. Given the recurrent nature of a majority of the Group's revenue, being in excess of 80% of total Group revenue, the Board believes that this performance is indicative of the performance for the second half of the year. The sales pipeline remains strong at approximately £93.0 million and the H1 sales targets were exceeded, incorporating 38 new client wins.

 

Given the increase in the Company's net debt position, the Board has resolved not to declare an interim dividend. With an anticipated improvement in net debt, the Board will review the Company's dividend policy at the time of the full-year results.

 

The Company has been very encouraged and appreciative of the supportive response from its employees, clients and prospective clients. The Company is focused on completing the matters outstanding in response to the forensic review, reporting the interim results and engaging with our valued clients and staff.

 

This announcement contains inside information.

 

 Enquiries:

 

Redcentric plc

via Tulchan Communications

Fraser Fisher, Chief Executive Officer

 

Peter Brotherton, Chief Financial Officer

 

 

 

Tulchan

+44 (0)20 7353 4200

James Macey White / Matt Low

 

 

 

Numis Securities Limited - Nomad & Joint Broker

+44 (0)20 7260 1000

Simon Willis / Ben Stoop / Oliver Hardy

 

 

 

finnCap Ltd - Joint Broker

+44 (0)20 7220 0500

Stuart Andrews / Rhys Williams

 

 

* Earnings before interest, tax, depreciation, amortisation of acquired intangibles, transaction and integration costs and share based payments.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFIEFELVLIR
Date   Source Headline
4th Jan 20227:00 amRNSTransaction in Own Shares
31st Dec 202112:27 pmRNSHolding(s) in Company
30th Dec 20217:00 amRNSTransaction in Own Shares
29th Dec 20217:00 amRNSHolding(s) in Company
24th Dec 20217:00 amRNSTransaction in Own Shares
23rd Dec 20214:48 pmRNSSave As You Earn Option Scheme
17th Dec 20218:22 amRNSNotice of subscription of warrants
24th Nov 20216:20 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Nov 20215:30 pmRNSDividend Update
19th Nov 20217:00 amRNSGrant of Options and Director/PDMR Shareholding
18th Nov 20217:01 amRNSHalf Year Results
18th Nov 20217:00 amRNSBoard changes
8th Nov 20212:58 pmRNSHolding(s) in Company
27th Oct 20217:00 amRNSTrading Update
20th Oct 20217:00 amRNSIssue of Equity
12th Oct 20217:00 amRNSExercise of Options
5th Oct 20217:00 amRNSIssue of Equity
30th Sep 20217:00 amRNSAcquisition of Piksel Industry Solutions Limited
29th Sep 20217:00 amRNSExercise of Options
9th Sep 20214:11 pmRNSResult of AGM
31st Aug 20217:00 amRNSSave As You Earn Share Option Scheme
9th Aug 20217:00 amRNSPublication of Annual Report and Notice of AGM
26th Jul 20217:00 amRNSIssue of Equity
23rd Jul 20212:55 pmRNSHolding(s) in Company
23rd Jul 202111:26 amRNSHolding(s) in Company
15th Jul 20217:00 amRNSPreliminary Results Announcement FY21
8th Jul 20217:00 amRNSBoard Change
7th Jul 20217:00 amRNSHolding(s) in Company
15th Jun 20217:00 amRNSDelay of Full Year Results
28th May 20217:00 amRNSExercise of options
28th Apr 20217:00 amRNSDirectorate Change
13th Apr 20215:27 pmRNSHolding(s) in Company
12th Apr 20212:47 pmRNSHolding(s) in Company
6th Apr 20217:00 amRNSTrading Statement
1st Apr 20217:00 amRNSExercise of Options
9th Mar 20215:00 pmRNSDirector/PDMR Shareholding
8th Mar 202112:52 pmRNSHolding(s) in Company
22nd Feb 20213:15 pmRNSHolding(s) in Company
19th Feb 20213:21 pmRNSHolding(s) in Company
19th Feb 202112:43 pmRNSHolding(s) in Company
8th Jan 20217:00 amRNSExercise of Options
6th Jan 20214:52 pmRNSHolding(s) in Company
6th Jan 20214:52 pmRNSHolding(s) in Company
6th Jan 20214:38 pmRNSHolding(s) in Company
23rd Dec 20207:00 amRNSDirector/PDMR Shareholding
22nd Dec 20205:13 pmRNSHolding(s) in Company
22nd Dec 20203:28 pmRNSHolding(s) in Company
21st Dec 20205:18 pmRNSHolding(s) in Company
9th Dec 20207:01 amRNSIssue of Options
9th Dec 20207:00 amRNSExercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.